Covidien   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dublin Ireland (2007)
Status: Acquired by Medtronic (2014)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1981

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

COVIDIEN

Active Ingredients

Marketed Drugs (1)

isosulfan blue (lymphazurin) (1981 NDA)

Drugs in Phase 4 Trials (1)

Key: Covidien (0) Acquired (1)

adalimumab (humira) (1 trial)

Drugs in Phase 3 Trials (1)

Key: Covidien (0) Acquired (1)

methacetin (1 trial)

Drugs in Phase 2 Trials (2)

Key: Covidien (0) Acquired (2)

glatiramer acetate (copaxone) (1 trial)

ocriplasmin (jetrea) (1 trial)

Drugs in Phase 1 Trials (4)

Key: Covidien (0) Acquired (4)

losartan (cozaar) (1 trial)

mk0736 (1 trial)

pioglitazone (actos) (1 trial)

simvastatin (zocor) (1 trial)

Drugs in Other Trials (2)

Key: Covidien (0) Acquired (2)

lactulose (cephulac) (1 trial)

rifaximin (xifaxan) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 10